Cargando…
Is there value in coronavirus disease 2019 vaccine and vaccine excipient skin testing or split dosing?
Autor principal: | Greenhawt, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712058/ https://www.ncbi.nlm.nih.gov/pubmed/36464396 http://dx.doi.org/10.1016/j.anai.2022.09.001 |
Ejemplares similares
-
Coronavirus disease 2019 vaccine hypersensitivity evaluated with vaccine and excipient allergy skin testing
por: Kohli-Pamnani, Anita, et al.
Publicado: (2022) -
Split-dosing of coronavirus disease 2019 vaccines
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
Split dosing of coronavirus disease 2019 vaccines provides noninferior antibody responsiveness to conventional vaccine dosing
por: Musa, Amal, et al.
Publicado: (2022) -
PEG/Polysorbate Skin Testing Has No Utility in the Assessment of Suspected Allergic Reactions to SARS-CoV-2 Vaccines
por: Greenhawt, Matthew, et al.
Publicado: (2021) -
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing
por: Wolfson, Anna R., et al.
Publicado: (2021)